Valproate (Epilepsy)

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6505
R17909		 Bànhidy (Valproate), 2011 Cardiovascular congenital abnormalities throughout pregnancy case control unexposed, sick Adjustment: No Matched 0.19 [0.01;4.28] C 0/5   5/15 5 5
ref
Total 1 studies 0.19 [0.01;4.28] 5 5
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Valproate), 2011Bànhidy, 2011 1 0.19[0.01; 4.28]550%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate0.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Valproate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0.19[0.01; 4.28]55 -NABànhidy (Valproate), 2011 1 Type of controls unexposed, sickunexposed, sick 0.19[0.01; 4.28]55 -NABànhidy (Valproate), 2011 1 Tags Adjustment   - No  - No 0.19[0.01; 4.28]55 -NABànhidy (Valproate), 2011 1 MatchedMatched 0.19[0.01; 4.28]55 -NABànhidy (Valproate), 2011 1 All studiesAll studies 0.19[0.01; 4.28]55 -NABànhidy (Valproate), 2011 10.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale31.03[4.16; 231.53]5540%NAMawer (Valproate) (Controls unexposed, disease free), 2010 D'Souza (Valproate) (Controls unexposed, disease free), 1991 2 unexposed, sick controlsunexposed, sick controls 2.26[1.24; 4.12]619780%NAThomas (Valproate) (Controls unexposed, sick), 2021 Vajda (Valproate) (Controls unexposed, sick), 2013 Bànhidy (Valproate), 2011 Mawer (Valproate) (Controls unexposed, sick), 2010 Artama (Valproate), 2005 Canger (Valproate), 1999 D'Souza (Valproate) (Controls unexposed, sick), 1991 7 exposed to other treatment, sick controlsexposed to other treatment, sick controls 4.17[2.74; 6.37]1213,5890%NAThomas (Valproate) (Controls exposed to Lamotrigine, sick), 2021 Tomson (Valproate), 2018 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Vajda (Valproate) (Controls exposed to Lamotrigine, sick), 2013 Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 Mawer (Valproate) (Controls exposed to Lamotrigine, sick), 2010 60.510.01.0